Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,024
archived clinical trials in
Infectious Disease

A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Orbactiv® (Oritavancin) for Infections Caused by Gram Positive Bacteria in a Real World Setting
Retrospective, Observational Evaluation of the Utilization, Outcomes, and Adverse Events Associated With Orbactiv® for the Treatment of Infections Presumed or Confirmed to be Caused by Gram Positive Bacteria in a Real World Setting
Status: Enrolling
Updated:  3/8/2018
Birmingham Infectious Disease and Infusion
mi
from
Birmingham, AL
A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Orbactiv® (Oritavancin) for Infections Caused by Gram Positive Bacteria in a Real World Setting
Retrospective, Observational Evaluation of the Utilization, Outcomes, and Adverse Events Associated With Orbactiv® for the Treatment of Infections Presumed or Confirmed to be Caused by Gram Positive Bacteria in a Real World Setting
Status: Enrolling
Updated: 3/8/2018
Birmingham Infectious Disease and Infusion
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Orbactiv® (Oritavancin) for Infections Caused by Gram Positive Bacteria in a Real World Setting
Retrospective, Observational Evaluation of the Utilization, Outcomes, and Adverse Events Associated With Orbactiv® for the Treatment of Infections Presumed or Confirmed to be Caused by Gram Positive Bacteria in a Real World Setting
Status: Enrolling
Updated:  3/8/2018
Santa Barbara Cottage Hospital
mi
from
Santa Barbara, CA
A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Orbactiv® (Oritavancin) for Infections Caused by Gram Positive Bacteria in a Real World Setting
Retrospective, Observational Evaluation of the Utilization, Outcomes, and Adverse Events Associated With Orbactiv® for the Treatment of Infections Presumed or Confirmed to be Caused by Gram Positive Bacteria in a Real World Setting
Status: Enrolling
Updated: 3/8/2018
Santa Barbara Cottage Hospital
mi
from
Santa Barbara, CA
Click here to add this to my saved trials
A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Orbactiv® (Oritavancin) for Infections Caused by Gram Positive Bacteria in a Real World Setting
Retrospective, Observational Evaluation of the Utilization, Outcomes, and Adverse Events Associated With Orbactiv® for the Treatment of Infections Presumed or Confirmed to be Caused by Gram Positive Bacteria in a Real World Setting
Status: Enrolling
Updated:  3/8/2018
Florida Infectious Disease Care
mi
from
Fort Myers, FL
A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Orbactiv® (Oritavancin) for Infections Caused by Gram Positive Bacteria in a Real World Setting
Retrospective, Observational Evaluation of the Utilization, Outcomes, and Adverse Events Associated With Orbactiv® for the Treatment of Infections Presumed or Confirmed to be Caused by Gram Positive Bacteria in a Real World Setting
Status: Enrolling
Updated: 3/8/2018
Florida Infectious Disease Care
mi
from
Fort Myers, FL
Click here to add this to my saved trials
A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Orbactiv® (Oritavancin) for Infections Caused by Gram Positive Bacteria in a Real World Setting
Retrospective, Observational Evaluation of the Utilization, Outcomes, and Adverse Events Associated With Orbactiv® for the Treatment of Infections Presumed or Confirmed to be Caused by Gram Positive Bacteria in a Real World Setting
Status: Enrolling
Updated:  3/8/2018
Infectious Diseases Associates of North Central Florida, LLC
mi
from
Ocala, FL
A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Orbactiv® (Oritavancin) for Infections Caused by Gram Positive Bacteria in a Real World Setting
Retrospective, Observational Evaluation of the Utilization, Outcomes, and Adverse Events Associated With Orbactiv® for the Treatment of Infections Presumed or Confirmed to be Caused by Gram Positive Bacteria in a Real World Setting
Status: Enrolling
Updated: 3/8/2018
Infectious Diseases Associates of North Central Florida, LLC
mi
from
Ocala, FL
Click here to add this to my saved trials
A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Orbactiv® (Oritavancin) for Infections Caused by Gram Positive Bacteria in a Real World Setting
Retrospective, Observational Evaluation of the Utilization, Outcomes, and Adverse Events Associated With Orbactiv® for the Treatment of Infections Presumed or Confirmed to be Caused by Gram Positive Bacteria in a Real World Setting
Status: Enrolling
Updated:  3/8/2018
WellStar Health System - Kennestone
mi
from
Marietta, GA
A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Orbactiv® (Oritavancin) for Infections Caused by Gram Positive Bacteria in a Real World Setting
Retrospective, Observational Evaluation of the Utilization, Outcomes, and Adverse Events Associated With Orbactiv® for the Treatment of Infections Presumed or Confirmed to be Caused by Gram Positive Bacteria in a Real World Setting
Status: Enrolling
Updated: 3/8/2018
WellStar Health System - Kennestone
mi
from
Marietta, GA
Click here to add this to my saved trials
A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Orbactiv® (Oritavancin) for Infections Caused by Gram Positive Bacteria in a Real World Setting
Retrospective, Observational Evaluation of the Utilization, Outcomes, and Adverse Events Associated With Orbactiv® for the Treatment of Infections Presumed or Confirmed to be Caused by Gram Positive Bacteria in a Real World Setting
Status: Enrolling
Updated:  3/8/2018
Snake River Research, PLLC
mi
from
Idaho Falls, ID
A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Orbactiv® (Oritavancin) for Infections Caused by Gram Positive Bacteria in a Real World Setting
Retrospective, Observational Evaluation of the Utilization, Outcomes, and Adverse Events Associated With Orbactiv® for the Treatment of Infections Presumed or Confirmed to be Caused by Gram Positive Bacteria in a Real World Setting
Status: Enrolling
Updated: 3/8/2018
Snake River Research, PLLC
mi
from
Idaho Falls, ID
Click here to add this to my saved trials
A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Orbactiv® (Oritavancin) for Infections Caused by Gram Positive Bacteria in a Real World Setting
Retrospective, Observational Evaluation of the Utilization, Outcomes, and Adverse Events Associated With Orbactiv® for the Treatment of Infections Presumed or Confirmed to be Caused by Gram Positive Bacteria in a Real World Setting
Status: Enrolling
Updated:  3/8/2018
St. Vincent Hospital and Health Care Center
mi
from
Indianapolis, IN
A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Orbactiv® (Oritavancin) for Infections Caused by Gram Positive Bacteria in a Real World Setting
Retrospective, Observational Evaluation of the Utilization, Outcomes, and Adverse Events Associated With Orbactiv® for the Treatment of Infections Presumed or Confirmed to be Caused by Gram Positive Bacteria in a Real World Setting
Status: Enrolling
Updated: 3/8/2018
St. Vincent Hospital and Health Care Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Orbactiv® (Oritavancin) for Infections Caused by Gram Positive Bacteria in a Real World Setting
Retrospective, Observational Evaluation of the Utilization, Outcomes, and Adverse Events Associated With Orbactiv® for the Treatment of Infections Presumed or Confirmed to be Caused by Gram Positive Bacteria in a Real World Setting
Status: Enrolling
Updated:  3/8/2018
Methodist Jennie Edmundson Hospital
mi
from
Council Bluffs, IA
A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Orbactiv® (Oritavancin) for Infections Caused by Gram Positive Bacteria in a Real World Setting
Retrospective, Observational Evaluation of the Utilization, Outcomes, and Adverse Events Associated With Orbactiv® for the Treatment of Infections Presumed or Confirmed to be Caused by Gram Positive Bacteria in a Real World Setting
Status: Enrolling
Updated: 3/8/2018
Methodist Jennie Edmundson Hospital
mi
from
Council Bluffs, IA
Click here to add this to my saved trials
A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Orbactiv® (Oritavancin) for Infections Caused by Gram Positive Bacteria in a Real World Setting
Retrospective, Observational Evaluation of the Utilization, Outcomes, and Adverse Events Associated With Orbactiv® for the Treatment of Infections Presumed or Confirmed to be Caused by Gram Positive Bacteria in a Real World Setting
Status: Enrolling
Updated:  3/8/2018
IDC Clinical Research, LLC
mi
from
Wichita, KA
A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Orbactiv® (Oritavancin) for Infections Caused by Gram Positive Bacteria in a Real World Setting
Retrospective, Observational Evaluation of the Utilization, Outcomes, and Adverse Events Associated With Orbactiv® for the Treatment of Infections Presumed or Confirmed to be Caused by Gram Positive Bacteria in a Real World Setting
Status: Enrolling
Updated: 3/8/2018
IDC Clinical Research, LLC
mi
from
Wichita, KA
Click here to add this to my saved trials
A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Orbactiv® (Oritavancin) for Infections Caused by Gram Positive Bacteria in a Real World Setting
Retrospective, Observational Evaluation of the Utilization, Outcomes, and Adverse Events Associated With Orbactiv® for the Treatment of Infections Presumed or Confirmed to be Caused by Gram Positive Bacteria in a Real World Setting
Status: Enrolling
Updated:  3/8/2018
Clinical Infectious Disease Specialists
mi
from
Las Vegas, NV
A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Orbactiv® (Oritavancin) for Infections Caused by Gram Positive Bacteria in a Real World Setting
Retrospective, Observational Evaluation of the Utilization, Outcomes, and Adverse Events Associated With Orbactiv® for the Treatment of Infections Presumed or Confirmed to be Caused by Gram Positive Bacteria in a Real World Setting
Status: Enrolling
Updated: 3/8/2018
Clinical Infectious Disease Specialists
mi
from
Las Vegas, NV
Click here to add this to my saved trials
A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Orbactiv® (Oritavancin) for Infections Caused by Gram Positive Bacteria in a Real World Setting
Retrospective, Observational Evaluation of the Utilization, Outcomes, and Adverse Events Associated With Orbactiv® for the Treatment of Infections Presumed or Confirmed to be Caused by Gram Positive Bacteria in a Real World Setting
Status: Enrolling
Updated:  3/8/2018
New York-Presbyterian/Brooklyn Methodist Hospital
mi
from
Brooklyn, NY
A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Orbactiv® (Oritavancin) for Infections Caused by Gram Positive Bacteria in a Real World Setting
Retrospective, Observational Evaluation of the Utilization, Outcomes, and Adverse Events Associated With Orbactiv® for the Treatment of Infections Presumed or Confirmed to be Caused by Gram Positive Bacteria in a Real World Setting
Status: Enrolling
Updated: 3/8/2018
New York-Presbyterian/Brooklyn Methodist Hospital
mi
from
Brooklyn, NY
Click here to add this to my saved trials
A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Orbactiv® (Oritavancin) for Infections Caused by Gram Positive Bacteria in a Real World Setting
Retrospective, Observational Evaluation of the Utilization, Outcomes, and Adverse Events Associated With Orbactiv® for the Treatment of Infections Presumed or Confirmed to be Caused by Gram Positive Bacteria in a Real World Setting
Status: Enrolling
Updated:  3/8/2018
Erie County Medical Center
mi
from
Buffalo, NY
A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Orbactiv® (Oritavancin) for Infections Caused by Gram Positive Bacteria in a Real World Setting
Retrospective, Observational Evaluation of the Utilization, Outcomes, and Adverse Events Associated With Orbactiv® for the Treatment of Infections Presumed or Confirmed to be Caused by Gram Positive Bacteria in a Real World Setting
Status: Enrolling
Updated: 3/8/2018
Erie County Medical Center
mi
from
Buffalo, NY
Click here to add this to my saved trials
A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Orbactiv® (Oritavancin) for Infections Caused by Gram Positive Bacteria in a Real World Setting
Retrospective, Observational Evaluation of the Utilization, Outcomes, and Adverse Events Associated With Orbactiv® for the Treatment of Infections Presumed or Confirmed to be Caused by Gram Positive Bacteria in a Real World Setting
Status: Enrolling
Updated:  3/8/2018
Trinity Health Medical Group
mi
from
Minot, ND
A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Orbactiv® (Oritavancin) for Infections Caused by Gram Positive Bacteria in a Real World Setting
Retrospective, Observational Evaluation of the Utilization, Outcomes, and Adverse Events Associated With Orbactiv® for the Treatment of Infections Presumed or Confirmed to be Caused by Gram Positive Bacteria in a Real World Setting
Status: Enrolling
Updated: 3/8/2018
Trinity Health Medical Group
mi
from
Minot, ND
Click here to add this to my saved trials
A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Orbactiv® (Oritavancin) for Infections Caused by Gram Positive Bacteria in a Real World Setting
Retrospective, Observational Evaluation of the Utilization, Outcomes, and Adverse Events Associated With Orbactiv® for the Treatment of Infections Presumed or Confirmed to be Caused by Gram Positive Bacteria in a Real World Setting
Status: Enrolling
Updated:  3/8/2018
Infectious Diseases Consultants of OKC
mi
from
Oklahoma City, OK
A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Orbactiv® (Oritavancin) for Infections Caused by Gram Positive Bacteria in a Real World Setting
Retrospective, Observational Evaluation of the Utilization, Outcomes, and Adverse Events Associated With Orbactiv® for the Treatment of Infections Presumed or Confirmed to be Caused by Gram Positive Bacteria in a Real World Setting
Status: Enrolling
Updated: 3/8/2018
Infectious Diseases Consultants of OKC
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Orbactiv® (Oritavancin) for Infections Caused by Gram Positive Bacteria in a Real World Setting
Retrospective, Observational Evaluation of the Utilization, Outcomes, and Adverse Events Associated With Orbactiv® for the Treatment of Infections Presumed or Confirmed to be Caused by Gram Positive Bacteria in a Real World Setting
Status: Enrolling
Updated:  3/8/2018
TruCare Internal Medicine and Infectious Diseases
mi
from
DuBois, PA
A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Orbactiv® (Oritavancin) for Infections Caused by Gram Positive Bacteria in a Real World Setting
Retrospective, Observational Evaluation of the Utilization, Outcomes, and Adverse Events Associated With Orbactiv® for the Treatment of Infections Presumed or Confirmed to be Caused by Gram Positive Bacteria in a Real World Setting
Status: Enrolling
Updated: 3/8/2018
TruCare Internal Medicine and Infectious Diseases
mi
from
DuBois, PA
Click here to add this to my saved trials
A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Orbactiv® (Oritavancin) for Infections Caused by Gram Positive Bacteria in a Real World Setting
Retrospective, Observational Evaluation of the Utilization, Outcomes, and Adverse Events Associated With Orbactiv® for the Treatment of Infections Presumed or Confirmed to be Caused by Gram Positive Bacteria in a Real World Setting
Status: Enrolling
Updated:  3/8/2018
Allegheny General Hospital
mi
from
Pittsburgh, PA
A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Orbactiv® (Oritavancin) for Infections Caused by Gram Positive Bacteria in a Real World Setting
Retrospective, Observational Evaluation of the Utilization, Outcomes, and Adverse Events Associated With Orbactiv® for the Treatment of Infections Presumed or Confirmed to be Caused by Gram Positive Bacteria in a Real World Setting
Status: Enrolling
Updated: 3/8/2018
Allegheny General Hospital
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Orbactiv® (Oritavancin) for Infections Caused by Gram Positive Bacteria in a Real World Setting
Retrospective, Observational Evaluation of the Utilization, Outcomes, and Adverse Events Associated With Orbactiv® for the Treatment of Infections Presumed or Confirmed to be Caused by Gram Positive Bacteria in a Real World Setting
Status: Enrolling
Updated:  3/8/2018
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Orbactiv® (Oritavancin) for Infections Caused by Gram Positive Bacteria in a Real World Setting
Retrospective, Observational Evaluation of the Utilization, Outcomes, and Adverse Events Associated With Orbactiv® for the Treatment of Infections Presumed or Confirmed to be Caused by Gram Positive Bacteria in a Real World Setting
Status: Enrolling
Updated: 3/8/2018
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Orbactiv® (Oritavancin) for Infections Caused by Gram Positive Bacteria in a Real World Setting
Retrospective, Observational Evaluation of the Utilization, Outcomes, and Adverse Events Associated With Orbactiv® for the Treatment of Infections Presumed or Confirmed to be Caused by Gram Positive Bacteria in a Real World Setting
Status: Enrolling
Updated:  3/8/2018
Center for Infectious Diseases & Travel Medicine
mi
from
El Paso, TX
A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Orbactiv® (Oritavancin) for Infections Caused by Gram Positive Bacteria in a Real World Setting
Retrospective, Observational Evaluation of the Utilization, Outcomes, and Adverse Events Associated With Orbactiv® for the Treatment of Infections Presumed or Confirmed to be Caused by Gram Positive Bacteria in a Real World Setting
Status: Enrolling
Updated: 3/8/2018
Center for Infectious Diseases & Travel Medicine
mi
from
El Paso, TX
Click here to add this to my saved trials
A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Orbactiv® (Oritavancin) for Infections Caused by Gram Positive Bacteria in a Real World Setting
Retrospective, Observational Evaluation of the Utilization, Outcomes, and Adverse Events Associated With Orbactiv® for the Treatment of Infections Presumed or Confirmed to be Caused by Gram Positive Bacteria in a Real World Setting
Status: Enrolling
Updated:  3/8/2018
Houston Center For Infectious Diseases
mi
from
The Woodlands, TX
A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Orbactiv® (Oritavancin) for Infections Caused by Gram Positive Bacteria in a Real World Setting
Retrospective, Observational Evaluation of the Utilization, Outcomes, and Adverse Events Associated With Orbactiv® for the Treatment of Infections Presumed or Confirmed to be Caused by Gram Positive Bacteria in a Real World Setting
Status: Enrolling
Updated: 3/8/2018
Houston Center For Infectious Diseases
mi
from
The Woodlands, TX
Click here to add this to my saved trials
A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Orbactiv® (Oritavancin) for Infections Caused by Gram Positive Bacteria in a Real World Setting
Retrospective, Observational Evaluation of the Utilization, Outcomes, and Adverse Events Associated With Orbactiv® for the Treatment of Infections Presumed or Confirmed to be Caused by Gram Positive Bacteria in a Real World Setting
Status: Enrolling
Updated:  3/8/2018
Infectious Disease and Pulmonary
mi
from
Victoria, TX
A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Orbactiv® (Oritavancin) for Infections Caused by Gram Positive Bacteria in a Real World Setting
Retrospective, Observational Evaluation of the Utilization, Outcomes, and Adverse Events Associated With Orbactiv® for the Treatment of Infections Presumed or Confirmed to be Caused by Gram Positive Bacteria in a Real World Setting
Status: Enrolling
Updated: 3/8/2018
Infectious Disease and Pulmonary
mi
from
Victoria, TX
Click here to add this to my saved trials
A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Orbactiv® (Oritavancin) for Infections Caused by Gram Positive Bacteria in a Real World Setting
Retrospective, Observational Evaluation of the Utilization, Outcomes, and Adverse Events Associated With Orbactiv® for the Treatment of Infections Presumed or Confirmed to be Caused by Gram Positive Bacteria in a Real World Setting
Status: Enrolling
Updated:  3/8/2018
Foot and Ankle Institute
mi
from
Saint George, UT
A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Orbactiv® (Oritavancin) for Infections Caused by Gram Positive Bacteria in a Real World Setting
Retrospective, Observational Evaluation of the Utilization, Outcomes, and Adverse Events Associated With Orbactiv® for the Treatment of Infections Presumed or Confirmed to be Caused by Gram Positive Bacteria in a Real World Setting
Status: Enrolling
Updated: 3/8/2018
Foot and Ankle Institute
mi
from
Saint George, UT
Click here to add this to my saved trials
Safety and Immunogenicity of Three Formulations of Takeda's Tetravalent Dengue Vaccine Candidate (TDV)
A Randomized, Double Blind, Phase 2 Study to Assess the Safety and Immunogenicity of Three Formulations of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Healthy Adults
Status: Enrolling
Updated:  3/9/2018
HOPE Research Institute
mi
from
Phoenix, AZ
Safety and Immunogenicity of Three Formulations of Takeda's Tetravalent Dengue Vaccine Candidate (TDV)
A Randomized, Double Blind, Phase 2 Study to Assess the Safety and Immunogenicity of Three Formulations of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Healthy Adults
Status: Enrolling
Updated: 3/9/2018
HOPE Research Institute
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Safety and Immunogenicity of Three Formulations of Takeda's Tetravalent Dengue Vaccine Candidate (TDV)
A Randomized, Double Blind, Phase 2 Study to Assess the Safety and Immunogenicity of Three Formulations of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Healthy Adults
Status: Enrolling
Updated:  3/9/2018
Anaheim Clinical Trials, LLC
mi
from
Anaheim, CA
Safety and Immunogenicity of Three Formulations of Takeda's Tetravalent Dengue Vaccine Candidate (TDV)
A Randomized, Double Blind, Phase 2 Study to Assess the Safety and Immunogenicity of Three Formulations of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Healthy Adults
Status: Enrolling
Updated: 3/9/2018
Anaheim Clinical Trials, LLC
mi
from
Anaheim, CA
Click here to add this to my saved trials
Safety and Immunogenicity of Three Formulations of Takeda's Tetravalent Dengue Vaccine Candidate (TDV)
A Randomized, Double Blind, Phase 2 Study to Assess the Safety and Immunogenicity of Three Formulations of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Healthy Adults
Status: Enrolling
Updated:  3/9/2018
Clinical Research Atlanta
mi
from
Stockbridge, GA
Safety and Immunogenicity of Three Formulations of Takeda's Tetravalent Dengue Vaccine Candidate (TDV)
A Randomized, Double Blind, Phase 2 Study to Assess the Safety and Immunogenicity of Three Formulations of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Healthy Adults
Status: Enrolling
Updated: 3/9/2018
Clinical Research Atlanta
mi
from
Stockbridge, GA
Click here to add this to my saved trials
Safety and Immunogenicity of Three Formulations of Takeda's Tetravalent Dengue Vaccine Candidate (TDV)
A Randomized, Double Blind, Phase 2 Study to Assess the Safety and Immunogenicity of Three Formulations of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Healthy Adults
Status: Enrolling
Updated:  3/9/2018
Advanced Clinical Research, Inc.
mi
from
Meridian, ID
Safety and Immunogenicity of Three Formulations of Takeda's Tetravalent Dengue Vaccine Candidate (TDV)
A Randomized, Double Blind, Phase 2 Study to Assess the Safety and Immunogenicity of Three Formulations of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Healthy Adults
Status: Enrolling
Updated: 3/9/2018
Advanced Clinical Research, Inc.
mi
from
Meridian, ID
Click here to add this to my saved trials
Safety and Immunogenicity of Three Formulations of Takeda's Tetravalent Dengue Vaccine Candidate (TDV)
A Randomized, Double Blind, Phase 2 Study to Assess the Safety and Immunogenicity of Three Formulations of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Healthy Adults
Status: Enrolling
Updated:  3/9/2018
Johnson County Clin-Trials
mi
from
Lenexa, KA
Safety and Immunogenicity of Three Formulations of Takeda's Tetravalent Dengue Vaccine Candidate (TDV)
A Randomized, Double Blind, Phase 2 Study to Assess the Safety and Immunogenicity of Three Formulations of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Healthy Adults
Status: Enrolling
Updated: 3/9/2018
Johnson County Clin-Trials
mi
from
Lenexa, KA
Click here to add this to my saved trials
Safety and Immunogenicity of Three Formulations of Takeda's Tetravalent Dengue Vaccine Candidate (TDV)
A Randomized, Double Blind, Phase 2 Study to Assess the Safety and Immunogenicity of Three Formulations of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Healthy Adults
Status: Enrolling
Updated:  3/9/2018
Clinical Research Center of Nevada, LLC
mi
from
Las Vegas, NV
Safety and Immunogenicity of Three Formulations of Takeda's Tetravalent Dengue Vaccine Candidate (TDV)
A Randomized, Double Blind, Phase 2 Study to Assess the Safety and Immunogenicity of Three Formulations of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Healthy Adults
Status: Enrolling
Updated: 3/9/2018
Clinical Research Center of Nevada, LLC
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Safety and Immunogenicity of Three Formulations of Takeda's Tetravalent Dengue Vaccine Candidate (TDV)
A Randomized, Double Blind, Phase 2 Study to Assess the Safety and Immunogenicity of Three Formulations of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Healthy Adults
Status: Enrolling
Updated:  3/9/2018
Tekton Research
mi
from
Austin, TX
Safety and Immunogenicity of Three Formulations of Takeda's Tetravalent Dengue Vaccine Candidate (TDV)
A Randomized, Double Blind, Phase 2 Study to Assess the Safety and Immunogenicity of Three Formulations of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Healthy Adults
Status: Enrolling
Updated: 3/9/2018
Tekton Research
mi
from
Austin, TX
Click here to add this to my saved trials
Milk Oriented Microbiota
Establishing a Milk Oriented Microbiota in Healthy Term Infants
Status: Enrolling
Updated:  3/9/2018
University of California, Davis Medical Center
mi
from
Sacramento, CA
Milk Oriented Microbiota
Establishing a Milk Oriented Microbiota in Healthy Term Infants
Status: Enrolling
Updated: 3/9/2018
University of California, Davis Medical Center
mi
from
Sacramento, CA
Click here to add this to my saved trials
Study of Long-term Safety, Efficacy Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis
An Open-label, Long-term Study to Evaluate the Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis
Status: Enrolling
Updated:  3/12/2018
Novartis Investigative Site
mi
from
Phoenix, AZ
Study of Long-term Safety, Efficacy Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis
An Open-label, Long-term Study to Evaluate the Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis
Status: Enrolling
Updated: 3/12/2018
Novartis Investigative Site
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Study of Long-term Safety, Efficacy Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis
An Open-label, Long-term Study to Evaluate the Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis
Status: Enrolling
Updated:  3/12/2018
Novartis Investigative site
mi
from
Boston, MA
Study of Long-term Safety, Efficacy Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis
An Open-label, Long-term Study to Evaluate the Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis
Status: Enrolling
Updated: 3/12/2018
Novartis Investigative site
mi
from
Boston, MA
Click here to add this to my saved trials
Home Testing of Day and Night Closed Loop With Pump Suspend Feature
An Open-label, Multi-centre, Randomised, Single-period, Parallel Design Study to Assess the Efficacy, Safety, Utility and Psychosocial Effect of 12 Week Day and Night Automated Closed Loop Glucose Control Combined With Pump Suspend Feature Compared to Sensor Augmented Insulin Pump Therapy in Youth and Adults With Type 1 Diabetes With Sub-optimal Glucose Control Under Free Living Conditions
Status: Enrolling
Updated:  3/12/2018
University of Colorado Denver
mi
from
Aurora, CO
Home Testing of Day and Night Closed Loop With Pump Suspend Feature
An Open-label, Multi-centre, Randomised, Single-period, Parallel Design Study to Assess the Efficacy, Safety, Utility and Psychosocial Effect of 12 Week Day and Night Automated Closed Loop Glucose Control Combined With Pump Suspend Feature Compared to Sensor Augmented Insulin Pump Therapy in Youth and Adults With Type 1 Diabetes With Sub-optimal Glucose Control Under Free Living Conditions
Status: Enrolling
Updated: 3/12/2018
University of Colorado Denver
mi
from
Aurora, CO
Click here to add this to my saved trials
Home Testing of Day and Night Closed Loop With Pump Suspend Feature
An Open-label, Multi-centre, Randomised, Single-period, Parallel Design Study to Assess the Efficacy, Safety, Utility and Psychosocial Effect of 12 Week Day and Night Automated Closed Loop Glucose Control Combined With Pump Suspend Feature Compared to Sensor Augmented Insulin Pump Therapy in Youth and Adults With Type 1 Diabetes With Sub-optimal Glucose Control Under Free Living Conditions
Status: Enrolling
Updated:  3/12/2018
International Diabetes Center-Park Nicollet
mi
from
Minneapolis, MN
Home Testing of Day and Night Closed Loop With Pump Suspend Feature
An Open-label, Multi-centre, Randomised, Single-period, Parallel Design Study to Assess the Efficacy, Safety, Utility and Psychosocial Effect of 12 Week Day and Night Automated Closed Loop Glucose Control Combined With Pump Suspend Feature Compared to Sensor Augmented Insulin Pump Therapy in Youth and Adults With Type 1 Diabetes With Sub-optimal Glucose Control Under Free Living Conditions
Status: Enrolling
Updated: 3/12/2018
International Diabetes Center-Park Nicollet
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Home Testing of Day and Night Closed Loop With Pump Suspend Feature
An Open-label, Multi-centre, Randomised, Single-period, Parallel Design Study to Assess the Efficacy, Safety, Utility and Psychosocial Effect of 12 Week Day and Night Automated Closed Loop Glucose Control Combined With Pump Suspend Feature Compared to Sensor Augmented Insulin Pump Therapy in Youth and Adults With Type 1 Diabetes With Sub-optimal Glucose Control Under Free Living Conditions
Status: Enrolling
Updated:  3/12/2018
International Diabetes Centre at Park Nicollet
mi
from
Minneapolis, MN
Home Testing of Day and Night Closed Loop With Pump Suspend Feature
An Open-label, Multi-centre, Randomised, Single-period, Parallel Design Study to Assess the Efficacy, Safety, Utility and Psychosocial Effect of 12 Week Day and Night Automated Closed Loop Glucose Control Combined With Pump Suspend Feature Compared to Sensor Augmented Insulin Pump Therapy in Youth and Adults With Type 1 Diabetes With Sub-optimal Glucose Control Under Free Living Conditions
Status: Enrolling
Updated: 3/12/2018
International Diabetes Centre at Park Nicollet
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Home Testing of Day and Night Closed Loop With Pump Suspend Feature
An Open-label, Multi-centre, Randomised, Single-period, Parallel Design Study to Assess the Efficacy, Safety, Utility and Psychosocial Effect of 12 Week Day and Night Automated Closed Loop Glucose Control Combined With Pump Suspend Feature Compared to Sensor Augmented Insulin Pump Therapy in Youth and Adults With Type 1 Diabetes With Sub-optimal Glucose Control Under Free Living Conditions
Status: Enrolling
Updated:  3/12/2018
University of Cambridge
mi
from
Cambridge,
Home Testing of Day and Night Closed Loop With Pump Suspend Feature
An Open-label, Multi-centre, Randomised, Single-period, Parallel Design Study to Assess the Efficacy, Safety, Utility and Psychosocial Effect of 12 Week Day and Night Automated Closed Loop Glucose Control Combined With Pump Suspend Feature Compared to Sensor Augmented Insulin Pump Therapy in Youth and Adults With Type 1 Diabetes With Sub-optimal Glucose Control Under Free Living Conditions
Status: Enrolling
Updated: 3/12/2018
University of Cambridge
mi
from
Cambridge,
Click here to add this to my saved trials
Antibiotic Treatment Trial for the PANDAS/PANS Phenotype
Antibiotic Treatment Trial for the PANDAS/PANS Phenotype
Status: Enrolling
Updated:  3/13/2018
Rothman Center for Neuropsychiatry
mi
from
Saint Petersburg, FL
Antibiotic Treatment Trial for the PANDAS/PANS Phenotype
Antibiotic Treatment Trial for the PANDAS/PANS Phenotype
Status: Enrolling
Updated: 3/13/2018
Rothman Center for Neuropsychiatry
mi
from
Saint Petersburg, FL
Click here to add this to my saved trials
Daptomycin for the Treatment of Severe Necrotizing Soft-Tissue Infections
Open Label, Single Center Study to Evaluate Higher Doses of Daptomycin in the Treatment of Patients With Severe Necrotizing Skin and Soft Tissue Infections.
Status: Enrolling
Updated:  3/14/2018
R Adams Cowley Shock Trauma Center, U. of Maryland Medical Center
mi
from
Baltimore, MD
Daptomycin for the Treatment of Severe Necrotizing Soft-Tissue Infections
Open Label, Single Center Study to Evaluate Higher Doses of Daptomycin in the Treatment of Patients With Severe Necrotizing Skin and Soft Tissue Infections.
Status: Enrolling
Updated: 3/14/2018
R Adams Cowley Shock Trauma Center, U. of Maryland Medical Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection
TBTC Study 26: Effectiveness and Tolerability of Weekly Rifapentine/Isoniazid for 3 Months Versus Daily Isoniazid for 9 Months for the Treatment of Latent Tuberculosis Infection
Status: Enrolling
Updated:  3/15/2018
Central Arkansas Veterans Health System
mi
from
Little Rock, AR
Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection
TBTC Study 26: Effectiveness and Tolerability of Weekly Rifapentine/Isoniazid for 3 Months Versus Daily Isoniazid for 9 Months for the Treatment of Latent Tuberculosis Infection
Status: Enrolling
Updated: 3/15/2018
Central Arkansas Veterans Health System
mi
from
Little Rock, AR
Click here to add this to my saved trials
Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection
TBTC Study 26: Effectiveness and Tolerability of Weekly Rifapentine/Isoniazid for 3 Months Versus Daily Isoniazid for 9 Months for the Treatment of Latent Tuberculosis Infection
Status: Enrolling
Updated:  3/15/2018
LA County/USC Medical Center
mi
from
Los Angeles, CA
Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection
TBTC Study 26: Effectiveness and Tolerability of Weekly Rifapentine/Isoniazid for 3 Months Versus Daily Isoniazid for 9 Months for the Treatment of Latent Tuberculosis Infection
Status: Enrolling
Updated: 3/15/2018
LA County/USC Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection
TBTC Study 26: Effectiveness and Tolerability of Weekly Rifapentine/Isoniazid for 3 Months Versus Daily Isoniazid for 9 Months for the Treatment of Latent Tuberculosis Infection
Status: Enrolling
Updated:  3/15/2018
UCSD Medical Center
mi
from
San Diego, CA
Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection
TBTC Study 26: Effectiveness and Tolerability of Weekly Rifapentine/Isoniazid for 3 Months Versus Daily Isoniazid for 9 Months for the Treatment of Latent Tuberculosis Infection
Status: Enrolling
Updated: 3/15/2018
UCSD Medical Center
mi
from
San Diego, CA
Click here to add this to my saved trials
Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection
TBTC Study 26: Effectiveness and Tolerability of Weekly Rifapentine/Isoniazid for 3 Months Versus Daily Isoniazid for 9 Months for the Treatment of Latent Tuberculosis Infection
Status: Enrolling
Updated:  3/15/2018
University of California at San Francisco
mi
from
San Francisco, CA
Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection
TBTC Study 26: Effectiveness and Tolerability of Weekly Rifapentine/Isoniazid for 3 Months Versus Daily Isoniazid for 9 Months for the Treatment of Latent Tuberculosis Infection
Status: Enrolling
Updated: 3/15/2018
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection
TBTC Study 26: Effectiveness and Tolerability of Weekly Rifapentine/Isoniazid for 3 Months Versus Daily Isoniazid for 9 Months for the Treatment of Latent Tuberculosis Infection
Status: Enrolling
Updated:  3/15/2018
Denver Department of Public Health and Hospitals
mi
from
Denver, CO
Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection
TBTC Study 26: Effectiveness and Tolerability of Weekly Rifapentine/Isoniazid for 3 Months Versus Daily Isoniazid for 9 Months for the Treatment of Latent Tuberculosis Infection
Status: Enrolling
Updated: 3/15/2018
Denver Department of Public Health and Hospitals
mi
from
Denver, CO
Click here to add this to my saved trials
Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection
TBTC Study 26: Effectiveness and Tolerability of Weekly Rifapentine/Isoniazid for 3 Months Versus Daily Isoniazid for 9 Months for the Treatment of Latent Tuberculosis Infection
Status: Enrolling
Updated:  3/15/2018
Washington DC VAMC
mi
from
Washington,
Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection
TBTC Study 26: Effectiveness and Tolerability of Weekly Rifapentine/Isoniazid for 3 Months Versus Daily Isoniazid for 9 Months for the Treatment of Latent Tuberculosis Infection
Status: Enrolling
Updated: 3/15/2018
Washington DC VAMC
mi
from
Washington,
Click here to add this to my saved trials
Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection
TBTC Study 26: Effectiveness and Tolerability of Weekly Rifapentine/Isoniazid for 3 Months Versus Daily Isoniazid for 9 Months for the Treatment of Latent Tuberculosis Infection
Status: Enrolling
Updated:  3/15/2018
Emory University, Department of Medicine
mi
from
Atlanta, GA
Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection
TBTC Study 26: Effectiveness and Tolerability of Weekly Rifapentine/Isoniazid for 3 Months Versus Daily Isoniazid for 9 Months for the Treatment of Latent Tuberculosis Infection
Status: Enrolling
Updated: 3/15/2018
Emory University, Department of Medicine
mi
from
Atlanta, GA
Click here to add this to my saved trials
Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection
TBTC Study 26: Effectiveness and Tolerability of Weekly Rifapentine/Isoniazid for 3 Months Versus Daily Isoniazid for 9 Months for the Treatment of Latent Tuberculosis Infection
Status: Enrolling
Updated:  3/15/2018
Chicago VA Medical Center (Lakeside)
mi
from
Chicago, IL
Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection
TBTC Study 26: Effectiveness and Tolerability of Weekly Rifapentine/Isoniazid for 3 Months Versus Daily Isoniazid for 9 Months for the Treatment of Latent Tuberculosis Infection
Status: Enrolling
Updated: 3/15/2018
Chicago VA Medical Center (Lakeside)
mi
from
Chicago, IL
Click here to add this to my saved trials
Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection
TBTC Study 26: Effectiveness and Tolerability of Weekly Rifapentine/Isoniazid for 3 Months Versus Daily Isoniazid for 9 Months for the Treatment of Latent Tuberculosis Infection
Status: Enrolling
Updated:  3/15/2018
Hines VA Medical Center
mi
from
Hines, IL
Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection
TBTC Study 26: Effectiveness and Tolerability of Weekly Rifapentine/Isoniazid for 3 Months Versus Daily Isoniazid for 9 Months for the Treatment of Latent Tuberculosis Infection
Status: Enrolling
Updated: 3/15/2018
Hines VA Medical Center
mi
from
Hines, IL
Click here to add this to my saved trials
Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection
TBTC Study 26: Effectiveness and Tolerability of Weekly Rifapentine/Isoniazid for 3 Months Versus Daily Isoniazid for 9 Months for the Treatment of Latent Tuberculosis Infection
Status: Enrolling
Updated:  3/15/2018
Johns Hopkins University School of Medicine
mi
from
Baltimore, MD
Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection
TBTC Study 26: Effectiveness and Tolerability of Weekly Rifapentine/Isoniazid for 3 Months Versus Daily Isoniazid for 9 Months for the Treatment of Latent Tuberculosis Infection
Status: Enrolling
Updated: 3/15/2018
Johns Hopkins University School of Medicine
mi
from
Baltimore, MD
Click here to add this to my saved trials
Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection
TBTC Study 26: Effectiveness and Tolerability of Weekly Rifapentine/Isoniazid for 3 Months Versus Daily Isoniazid for 9 Months for the Treatment of Latent Tuberculosis Infection
Status: Enrolling
Updated:  3/15/2018
Boston Med Ctr
mi
from
Boston, MA
Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection
TBTC Study 26: Effectiveness and Tolerability of Weekly Rifapentine/Isoniazid for 3 Months Versus Daily Isoniazid for 9 Months for the Treatment of Latent Tuberculosis Infection
Status: Enrolling
Updated: 3/15/2018
Boston Med Ctr
mi
from
Boston, MA
Click here to add this to my saved trials
Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection
TBTC Study 26: Effectiveness and Tolerability of Weekly Rifapentine/Isoniazid for 3 Months Versus Daily Isoniazid for 9 Months for the Treatment of Latent Tuberculosis Infection
Status: Enrolling
Updated:  3/15/2018
New Jersey Medical School
mi
from
Newark, NJ
Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection
TBTC Study 26: Effectiveness and Tolerability of Weekly Rifapentine/Isoniazid for 3 Months Versus Daily Isoniazid for 9 Months for the Treatment of Latent Tuberculosis Infection
Status: Enrolling
Updated: 3/15/2018
New Jersey Medical School
mi
from
Newark, NJ
Click here to add this to my saved trials
Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection
TBTC Study 26: Effectiveness and Tolerability of Weekly Rifapentine/Isoniazid for 3 Months Versus Daily Isoniazid for 9 Months for the Treatment of Latent Tuberculosis Infection
Status: Enrolling
Updated:  3/15/2018
Columbia University/Presbyterian Medical Center
mi
from
New York, NY
Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection
TBTC Study 26: Effectiveness and Tolerability of Weekly Rifapentine/Isoniazid for 3 Months Versus Daily Isoniazid for 9 Months for the Treatment of Latent Tuberculosis Infection
Status: Enrolling
Updated: 3/15/2018
Columbia University/Presbyterian Medical Center
mi
from
New York, NY
Click here to add this to my saved trials